Chirayu Amin
#389Chairman & CEO
78
Age
58y
Exp
58y
Tenure
6/10
Risk
🎓 Bachelor of Arts/Science · Baroda University
📜 MBA · Seton Hall University USA
🏛️ None
CompensationTBP
Personality
5
Open
6
Cons
5
Extr
5
Agre
4
Neur
Alembic Pharma
Healthcare · Mid Cap
Mature Stable · Hierarchical
About
Chirayu Amin is the Chairman & CEO of Alembic Pharma, a Mid Cap company in the Healthcare sector with a market cap of ₹14K Cr. A Visionary leader with 58 years of experience, he is known for intuition-driven decision-making and organic builder strategy. Demonstrates a long-term strategic commitment to R&D and expanding presence in international markets.
FAQ
What is Chirayu Amin's leadership style?
Chirayu Amin is classified as a Visionary leader. He is intuition-driven in decision-making, with a dynasty builder motivation and steady-marathon pace of execution.
What is Chirayu Amin's educational background?
Chirayu Amin holds a Bachelor of Arts/Science from Baroda University and a MBA from Seton Hall University USA.
Who is the CEO of Alembic Pharma?
Chirayu Amin is the Chairman & CEO of Alembic Pharma. He has been with the company for 58 years and in the current role for 9 years.
Leadership DNA
ArchetypeVisionary
MotivationDynasty Builder
CrisisSteady Hand
DecisionIntuition-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerSteady Employer
BrandTrusted
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Demonstrates a long-term strategic commitment to R&D and expanding presence in international markets.”
⚡ Crisis●●●●○
Amin has maintained Alembic's focus on its core pharmaceutical portfolio through various industry cycles, prioritizing long-term stability over radical restructuring.
🎯 Motivation●●●●●
As a member of the Amin family, he has focused on ensuring the continuity and multi-generational legacy of the Alembic group.
👥 People●●●●○
The company maintains a culture deeply rooted in long-term loyalty and internal stability, characteristic of the family-run management style he oversees.
📈 Growth●●●●○
Alembic's growth under his leadership has been primarily driven by significant investments in R&D and manufacturing capacity expansion rather than aggressive M&A.
💡 Innovation●●●●○
Focuses on building a robust portfolio of generic drugs and complex generics by leveraging established manufacturing capabilities rather than pioneering novel drug discovery.
🏃 Pace●●●●○
Maintains a predictable, long-term operational rhythm characteristic of a legacy pharmaceutical firm with over a century of history.
🌱 Purpose●●●○○
Operates primarily as a traditional pharmaceutical manufacturer where ESG initiatives are managed as regulatory compliance rather than core strategic drivers.
🏷️ Brand●●●●○
Leverages over 100 years of institutional legacy and consistent manufacturing reliability to maintain credibility with healthcare providers and partners.
🤝 Customer●●●●○
Primarily operates through institutional sales, distributors, and global partnerships for its API and finished dosage form exports.
💼 Employer●●●○○
Known for providing stable, long-term employment within a traditional, hierarchical corporate structure typical of established Vadodara-based industrial houses.
📋 Mandate
To break out of competitive commoditization, the company needs to shift its focus toward high-margin specialty and complex generic R&D.
🏢 Culture●●●●○
Long-standing legacy pharmaceutical company characterized by family stewardship and established, conservative corporate procedures.
Financials
Revenue FY25₹7K Cr
PAT FY25₹583 Cr
Rev CAGR 5Y7.7%
OPM11.2%
NPM8.9%
ROE11.2%
ROCE13.7%
P/E21.1
Fwd P/E15.7
P/B2.5
D/E28
Promoter70.6%
Institutional17%
Mkt Cap₹14K Cr
Compensation
To Be Published
Data being verified from audited reports
